Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. (Q51658537)
Jump to navigation
Jump to search
scientific article published on 23 January 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. |
scientific article published on 23 January 2015 |
Statements
Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma (English)
Peter Vuylsteke
Teresa Moran
Marie-Pascale Graas
Daniella Galdermans
Jean-Luc Canon
Denis Schallier
Lore Decoster
Erik Teugels
Dan Massey
Vikram K Chand
Johan Vansteenkiste
23 January 2015